---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-024613"
form_type: "8-K"
ticker: "SCNX"
cik: "0001382574"
company_name: "Scienture Holdings, Inc."
filed_at: "2023-07-14T23:59:59+00:00"
generated_at: "2026-06-13T08:08:01.937199+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TRxADE Health amends merger with Superlatus; adds share rights for existing holders

## Summary
- Superlatus shareholders get 30,821,941 shares at $7.30: 136,441 common (19.99% post-merger) and 306,855 Series B convertible preferred (100:1).
- TRxADE to issue non-transferable MEDS Rights: 7 rights per share held, each for one free common share, record date one day before closing.
- Ancillary document deadline extended to 10 days; certain MEDS equity holders will sign lock-up agreements.
- Rights holders must sign Registration Rights Agreement; shares locked for one year post-closing.

## SEC filing metadata
- accession: 0001493152-23-024613
- form_type: 8-K
- ticker: SCNX
- cik: 0001382574
- company_name: Scienture Holdings, Inc.
- filed_at: 2023-07-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382574/000149315223024613/0001493152-23-024613-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382574/000149315223024613/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-024613
- JSON: https://secwatch.observer/filing/0001493152-23-024613.json
- Plain text: https://secwatch.observer/filing/0001493152-23-024613.txt

## Key facts
- Material Agreements
  Scienture Holdings, Inc. entered into Amended and Restated Agreement and Plan of Merger with Superlatus, Inc. valued at 30,821,941 shares of Company stock at $7.30 per share, comprised of 136,441 shares of common stock ( (effective 2023-07-14).
  - Action: entry
  - Agreement: merger
  - Counterparty: Superlatus, Inc.
  - Value: 30,821,941 shares of Company stock at $7.30 per share, comprised of 136,441 shares of common stock (
  - Effective: 2023-07-14
  source text: As previously disclosed, on June 30, 2023, TRxADE HEALTH, Inc., a Delaware corporation (the “Company” or “MEDS”), entered into an Agreement and Plan of Merger (the “Original Merger Agreement”) with Superlatus, Inc., a U.S.-based holding company of food products and distribution capabilities (“Superlatus”). On July 14, 2023, the Company and Superlatus entered into an Amended and Restated Agreement and Plan of Merger (the “A&R Merger Agreement”; the transactions contemplated thereby, the “Merger”), which amends the merger consideration payable to the shareholders of Superlatus and adds the issuance of non-transferrable rights to receive shares of common stock of the Company at no cost to the shareholders of the Company in connection with the Merger.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1382574/000149315223024613/0001493152-23-024613-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.